Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health benefits that come with my job. That grim ...

Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health ...

The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...